A multicenter open-label phase II trial to evaluate autologous fecal micobiota transfer in combination with first line immune anti-PD-1 and chemotherapy according to investigator's choice for treatment beyond progression in patients with advanced esophageal and gastric adenocarcinoma

autologous Fecal Microbiota Transfer (aFMT)

Status: In Vorbereitung

Klinische Settings

Beteiligte

Identifier

Kontakt